Lantern Pharma (NASDAQ: LTRN) is developing a number of clinical trials, using its proprietary drug candidates and computational biology and machine learning platform, to target conditions with unmet medical needs. The company was featured in a recent article that discussed its preparation for the launch of a trial targeting a rare pediatric disease, planned for Q1 2026. This comes “in the wake of its optimistic meeting with the U.S. Food and Drug Administration (‘FDA’) to receive critical guidance on the company’s trial design and the FDA’s regulatory pathway… Lantern Pharma is developing its clinical trial with the hope of demonstrating the efficacy of its investigational therapy LP-184/STAR-001 in combatting central nervous system (‘CNS’) cancers, including Atypical Teratoid Rhabdoid Tumor (‘ATRT’). The LP-184/STAR-001 therapy is designed to work synergistically with diuretic (water pill) spironolactone and other potential combination regimens in treating the childhood brain cancers,” reads the article. “Lantern’s program for ATRT has received Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA, and the company is preparing to submit an investigational new drug (‘IND’) amendment.”
“We are thrilled with the constructive dialogue and positive feedback from our Type C meeting with the FDA,” said Lantern President and CEO Panna Sharma. “This guidance not only reinforces our trial design but also highlights the potential of our AI platform, RADR(R), in identifying and optimizing combination regimens like spironolactone for these devastating pediatric CNS cancers.”
To view the full article, visit https://ibn.fm/YCU5D
About Lantern Pharma Inc.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. The company’s proprietary AI and machine learning platform, RADR(R), leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has accelerated the development of its growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers. On average, Lantern’s newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program.
NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN